Trial Profile

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel
Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-B21
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

09 Jun 2025 Planned End Date changed from 31 May 2026 to 15 Sep 2026.
09 Jun 2025 Planned primary completion date changed from 31 May 2026 to 15 Sep 2026.
17 Feb 2025 Planned End Date changed from 18 Jun 2025 to 31 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com